LOW GRADE SEROUS OVARIAN CANCER
Clinical trials for LOW GRADE SEROUS OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new LOW GRADE SEROUS OVARIAN CANCER trials appear
Sign up with your email to follow new studies for LOW GRADE SEROUS OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug attack on ovarian cancer shows promise in early trial
Disease control Recruiting nowThis study tests a combination of three drugs (avutometinib, defactinib, and letrozole) in 20 women with low-grade serous ovarian cancer who cannot have surgery right away. The goal is to see if the combo shrinks tumors and is safe. This is a Phase 2 trial, so it's still early, b…
Matched conditions: LOW GRADE SEROUS OVARIAN CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 10:44 UTC
-
New hope for rare ovarian cancer: drug combo targets tumor growth
Disease control Recruiting nowThis study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 adults whose cancer returned after platinum therapy will be randomly assigned to the combo …
Matched conditions: LOW GRADE SEROUS OVARIAN CANCER
Phase: PHASE3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New antibody combo shows promise for Tough-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests an experimental drug called ubamatamab, given alone or with another drug (cemiplimab), for people with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back. The main goals are to check safety, find the best dose, and see if the drugs can …
Matched conditions: LOW GRADE SEROUS OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:51 UTC